Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Oct 13

PMID 34638949

Citations 7

Authors

Yi-Fang Yang

Hao-Wen Chuang

Wei-Ting Kuo

Bo-Syuan Lin

Yu-Chan Chang

Affiliations

Soon will be listed here.

Abstract

Urothelial cancer is a malignant tumor with metastatic ability and high mortality. Malignant tumors of the urinary system include upper tract urothelial cancer and bladder cancer. In addition to typical genetic alterations and epigenetic modifications, metabolism-related events also occur in urothelial cancer. This metabolic reprogramming includes aberrant expression levels of genes, metabolites, and associated networks and pathways. In this review, we summarize the dysfunctions of glycolytic enzymes in urothelial cancer and discuss the relevant phenotype and signal transduction. Moreover, we describe potential prognostic factors and risks to the survival of clinical cancer patients. More importantly, based on several available databases, we explore relationships between glycolytic enzymes and genetic changes or drug responses in urothelial cancer cells. Current advances in glycolysis-based inhibitors and their combinations are also discussed. Combining all of the evidence, we indicate their potential value for further research in basic science and clinical applications.

Citing Articles

Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer.

Wang X, Pan J, Guan Q, Ren N, Wang P, Wei M Front Pharmacol. 2023; 14:1215296.

PMID: 37781694 PMC: 10533998. DOI: 10.3389/fphar.2023.1215296.

Oncogenic Alterations of Metabolism Associated with Resistance to Chemotherapy.

Ghasemi F, Farkhondeh T, Samarghandian S, Ghasempour A, Shakibaie M Curr Mol Med. 2023; 24(7):856-866.

PMID: 37350008 DOI: 10.2174/1566524023666230622104625.

Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy.

Afonso J, Goncalves C, Costa M, Ferreira D, Santos L, Longatto-Filho A Cancers (Basel). 2023; 15(3).

PMID: 36765947 PMC: 9913750. DOI: 10.3390/cancers15030982.

Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy.

Koguchi D, Matsumoto K, Ikeda M, Shimizu Y, Nakamura M, Shiono Y Int J Mol Sci. 2022; 23(20).

PMID: 36292976 PMC: 9602626. DOI: 10.3390/ijms232012119.

Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.

Huang Z, Yan Y, Wang T, Wang Z, Cai J, Cao X J Transl Med. 2022; 20(1):315.

PMID: 35836227 PMC: 9281045. DOI: 10.1186/s12967-022-03509-1.

References

Balihodzic A, Barth D, Prinz F, Pichler M . Involvement of Long Non-Coding RNAs in Glucose Metabolism in Cancer. Cancers (Basel). 2021; 13(5). PMC: 7956509. DOI: 10.3390/cancers13050977. View

Schmidt M, Dringen R . Differential effects of iodoacetamide and iodoacetate on glycolysis and glutathione metabolism of cultured astrocytes. Front Neuroenergetics. 2009; 1:1. PMC: 2691547. DOI: 10.3389/neuro.14.001.2009. View

Chen X, Li A, Sun B, Yang Y, Han Y, Yuan X . 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8):978-990. DOI: 10.1038/s41556-019-0361-y. View

Lu W, Gao J, Yang J, Cao Y, Jiang L, Li M . Down-Regulated Phosphoglycerate Kinase 1 Expression Is Associated With Poor Prognosis in Patients With Gallbladder Cancer. Medicine (Baltimore). 2015; 94(49):e2244. PMC: 5008514. DOI: 10.1097/MD.0000000000002244. View

Fei X, Qi M, Wu B, Song Y, Wang Y, Li T . MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett. 2012; 586(4):392-7. DOI: 10.1016/j.febslet.2012.01.006. View

Powers J, Kiesman N, Tran C, Brown J, Bevilacqua V . Lactate dehydrogenase kinetics and inhibition using a microplate reader. Biochem Mol Biol Educ. 2011; 35(4):287-92. DOI: 10.1002/bmb.74. View

Yu X, Li S . Non-metabolic functions of glycolytic enzymes in tumorigenesis. Oncogene. 2016; 36(19):2629-2636. DOI: 10.1038/onc.2016.410. View

Chen T, Huang Z, Tian Y, Wang H, Ouyang P, Chen H . Role of triosephosphate isomerase and downstream functional genes on gastric cancer. Oncol Rep. 2017; 38(3):1822-1832. DOI: 10.3892/or.2017.5846. View

Giovannetti E, Leon L, Gomez V, Zucali P, Minutolo F, Peters G . A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. Nucleosides Nucleotides Nucleic Acids. 2016; 35(10-12):643-651. DOI: 10.1080/15257770.2016.1149193. View

10.

Scholtes M, de Jong F, Zuiverloon T, Theodorescu D . Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy. Cancers (Basel). 2021; 13(2). PMC: 7830378. DOI: 10.3390/cancers13020288. View

11.

Li L, Liang Y, Kang L, Liu Y, Gao S, Chen S . Transcriptional Regulation of the Warburg Effect in Cancer by SIX1. Cancer Cell. 2018; 33(3):368-385.e7. DOI: 10.1016/j.ccell.2018.01.010. View

12.

Su Q, Peng M, Zhang Y, Xu W, Darko K, Tao T . Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. Am J Cancer Res. 2016; 6(2):498-508. PMC: 4859676. View

13.

Huang K, Liang Q, Zhou Y, Jiang L, Gu W, Luo M . A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 2019; 30(6):1107-1119.e8. DOI: 10.1016/j.cmet.2019.09.014. View

14.

Hsieh H, Jou Y, Tung C, Tsai Y, Wang Y, Chi C . Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment. Oncogene. 2017; 37(5):673-686. DOI: 10.1038/onc.2017.375. View

15.

Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

16.

Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L . Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther. 2017; 16(4):614-624. PMC: 5539948. DOI: 10.1158/1535-7163.MCT-15-1010. View

17.

Tang S, Ho M, Cho H, Lin Y, Sun G, Chi K . Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int J Cancer. 2008; 123(12):2840-8. DOI: 10.1002/ijc.23888. View

18.

Wu C, Ho Y, Tsai C, Wang Y, Tseng H, Wei P . In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. Int J Cancer. 2009; 124(9):2210-9. DOI: 10.1002/ijc.24189. View

19.

Wang Z, Chen J, Yang L, Cao M, Yu Y, Zhang R . Single-Cell Sequencing-Enabled Hexokinase 2 Assay for Noninvasive Bladder Cancer Diagnosis and Screening by Detecting Rare Malignant Cells in Urine. Anal Chem. 2020; 92(24):16284-16292. DOI: 10.1021/acs.analchem.0c04282. View

20.

Wang Y, Hao F, Nan Y, Qu L, Na W, Jia C . PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis. Int J Biol Sci. 2018; 14(13):1883-1891. PMC: 6231221. DOI: 10.7150/ijbs.27854. View